A randomised controlled trial of the probiotic Bifidobacterium breve BBG-001 in preterm babies to prevent sepsis, necrotising enterocolitis and death: the Probiotics in Preterm infantS (PiPS) trial.
- 2016-08
- RCT · n = 1,315
- Health Technology Assessment 20(66)
- K. Costeloe
- U. Bowler
- P. Brocklehurst
- P. Hardy
- Paul Heal
- E. Juszczak
- A. King
- N. Panton
- F. Stacey
- A. Whiley
- M. Wilks
- M. Millar
- PubMed: 27594381
- DOI: 10.3310/hta20660
- High evidence
- Large Human Trial
- Infants
There was no evidence of benefit for the primary outcomes {sepsis: 11.2% vs. 11.7% [adjusted relative risk (RR) 0.97, 95% confidence interval (CI) 0.73 to 1.29]}
- Effect
- Neutral
- Effect size
- Small
- Significant
- No